Daxor Corporation (DXR)
| Market Cap | 63.75M +81.9% |
| Revenue (ttm) | 26,688 -77.7% |
| Net Income | 9.17M +1,609.7% |
| EPS | 1.81 +1,567.3% |
| Shares Out | 5.83M |
| PE Ratio | 6.04 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,978 |
| Open | 11.21 |
| Previous Close | 11.12 |
| Day's Range | 10.50 - 11.50 |
| 52-Week Range | 7.10 - 14.76 |
| Beta | 0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 27, 2026 |
About DXR
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Financial Performance
In 2025, Daxor's revenue was $26,688, a decrease of -77.71% compared to the previous year's $119,714. Earnings were $9.17 million, an increase of 1609.71%.
Financial StatementsNews
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the Am...
Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript
Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in ...
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will par...
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), ...
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
Expansion Leverages Daxor's ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global lea...
Daxor Corporation Announces $9 Million Registered Direct Offering
OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors...
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the gl...
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit
Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global lea...
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporat...
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leade...
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2...
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh wi...
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in...
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume m...
Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
Continued Integration of Daxor's ezBVA Lab Service and On-Site Analyzers Fuels Positive Outlook Oak Ridge, TN, July 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in b...
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Da...
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DX...
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology
Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measuremen...
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
Daxor's Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume ...
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader...
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
Precise Volume Measurement Prior to Discharge Identifies Mortality Risk Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo
BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
Regional Medical Leaders Embrace Daxor's ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement techn...